With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026. FDA approval could add to the pressure on Sotyktu, which generated $206 ...
OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...
Your health should be your top priority at all times. It is the foundation for everything else that you do in life. You know ...
ProLogium, a leader in solid-state battery R&D and mass production, today announced that it has signed a Memorandum of Understanding (MoU) with Delta, a global provider of power management and thermal ...
Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
California healthcare innovator Amgen, which already has facilities at Cambridge Science Park, has made a new and incisive acquisition in the UK - buying Oxford University spin-out Dark Blue ...
Many EV drivers unknowingly shorten their car’s battery life. Learn which habits to unlearn if you want your electric vehicle ...
Aggregate revenue across the top 10 brokers for 2025 was just over £13bn - an amount that summed up brokerage across the ...
For the BCIA, 2025 has been a thoroughly successful and positive year. With more than 270 apprentices on its Level 4 Building ...
As electric vehicles began to appear more frequently on Vietnamese streets, many people assumed that repairing them was ...
We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the ...
Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback